Thromboembolic Events in Severe COVID-19 Patients

Incidence of Thromboembolic Events and Prognosis of COVID-19 Patients Hospitalized in Intensive Care Units in France

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04405869

Acronym

COVICLOT

Enrollment

300

Registered

2020-05-28

Start date

2020-04-29

Completion date

2021-04-30

Last updated

2020-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Thromboembolism

Keywords

Covid-19, Thrombosis, D-Dimers, Anticoagulation

Brief summary

The main objective of this study is to describe the incidence of thromboembolic events in a population of patients hospitalized in intensive care units in France for severe COVID-19. The secondary objective of this study is to describe the evolution of hemostasis parameters during the first two weeks of intensive care hospitalization and to evaluate the influence of different anticoagulation regimens on these parameters and on the incidence of thromboembolic events

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Confirmed infection with the Sars-CoV-2 virus (RT-PCR) * Hospitalization in Intensive Care Unit * Age over 18 years Old

Exclusion criteria

* Refusal of the patient to participate in data collection

Design outcomes

Primary

Measure	Time frame
Analysis of incidence of thromboembolic events in patients with Sars-CoV-2	1 month

Countries

France

Contacts

Primary ContactCharles TACQUARD, MD

charlesambroise.tacquard@chru-strasbourg.fr33 3 69 55 16 08

Backup ContactSaïd CHAYER, PhD, HDR

said.chayer@chru-strasbourg.fr33 3 88 11 66 90

Outcome results